Placebo News and Research

RSS

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

31 Aug 2018

UniSA researchers unearth potential cure for obesity

It costs the global economy an estimated US$2 trillion annually and has been dubbed a modern day health epidemic, but new research from the University of South Australia has unearthed a possible cure for obesity – and it is as plain as dirt!

31 Aug 2018

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Pfizer Inc. announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).

30 Aug 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Clinical trial: Promising drug slows brain shrinkage in progressive MS patients

A promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland Clinic. Very limited therapies are currently available for this disabling form of the disease.

30 Aug 2018

Component of cannabis could help in psychosis

Researchers from King’s College London have now found how the chemical cannabidiol or CBD from cannabis can reduce the abnormal brain activity in patients who are at risk of psychosis. The study was published in the latest issue of the journal JAMA Psychiatry.

30 Aug 2018

Ketamine’s role in treatment of depression: Study

The anaesthetic drug Ketamine has been shown to be beneficial in some cases of depression and suicidal ideation which have typically failed to respond to other standard antidepressant medications. A new study has explored the actual workings of ketamine in depression and found that the drug can act on the same receptors as opioid pain relievers.

30 Aug 2018

Ketamine's acute antidepressant effect requires opioid system activation, finds study

A new study appearing online today from the American Journal of Psychiatry finds that ketamine's acute antidepressant effect requires opioid system activation, the first time that a receptor site has been shown in humans to be necessary for any antidepressant's mechanism of action.

29 Aug 2018

Drug used for chest pain does not decrease chance of first occurrence of ventricular arrhythmias

A clinical trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine was safe but didn't significantly decrease the likelihood of the first occurrence of ventricular tachycardia, ventricular fibrillation or death in this high-risk population.

29 Aug 2018

Blood pressure lowering therapy and statins continue to improve survival in patients with hypertension

Blood pressure and cholesterol lowering drugs continue to improve survival in patients with hypertension after more than a decade, according to late breaking results from the ASCOT Legacy study presented at ESC Congress 2018 and published in The Lancet.

28 Aug 2018

Blood pressure medication slows enlargement of the aorta in patients with Marfan syndrome

Treatment with a drug to lower blood pressure slows enlargement (dilatation) of the aorta in children and young adults with Marfan syndrome, according to late breaking results from the AIMS trial presented today in a Hot Line Session at ESC Congress 2018.

28 Aug 2018

Daily use of aspirin does not reduce occurrence of major cardiovascular events, finds ARRIVE trial

The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear.

28 Aug 2018

Low dose Aspirin daily – benefits and risks measured in two studies

Low dose Aspirin has been advocated to reduce the risk of a second heart attack or a stroke or other heart problems in persons who have had one episode. A major new study published in the Lancet, has found that taking Aspirin to prevent the first heart attack fails to work. In fact the risks of taking low dose Aspirin to prevent the first heart attack outweigh the benefits.

27 Aug 2018

Amphetamine regimen does not improve post-stroke motor recovery

A pilot clinical trial exploring the benefit of d-amphetamine combined with physical therapy for stroke patients found no evidence that the regimen improved post-stroke motor recovery.

27 Aug 2018

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.

27 Aug 2018

Aspirin appears to cause major bleeds and have no effect on cancers

Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers.

27 Aug 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

ARRIVE study assesses impact of daily aspirin on heart attacks, strokes

The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late breaking results from the ARRIVE study presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in the Lancet.

27 Aug 2018

Study demonstrates cardiovascular safety of weight loss drug

A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.

27 Aug 2018

Fish oil supplements do not reduce risk of cardiovascular events in patients with diabetes

Fish oil supplements do not prevent heart attacks or strokes in patients with diabetes, according to late breaking results from the ASCEND trial presented today in a Hot Line Session at ESC Congress 2018 and published in the New England Journal of Medicine.

27 Aug 2018

Placebo News and Research

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

UniSA researchers unearth potential cure for obesity

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Clinical trial: Promising drug slows brain shrinkage in progressive MS patients

Component of cannabis could help in psychosis

Ketamine’s role in treatment of depression: Study

Ketamine's acute antidepressant effect requires opioid system activation, finds study

Drug used for chest pain does not decrease chance of first occurrence of ventricular arrhythmias

Blood pressure lowering therapy and statins continue to improve survival in patients with hypertension

Blood pressure medication slows enlargement of the aorta in patients with Marfan syndrome

Daily use of aspirin does not reduce occurrence of major cardiovascular events, finds ARRIVE trial

Low dose Aspirin daily – benefits and risks measured in two studies

Amphetamine regimen does not improve post-stroke motor recovery

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

Aspirin appears to cause major bleeds and have no effect on cancers

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

ARRIVE study assesses impact of daily aspirin on heart attacks, strokes

Study demonstrates cardiovascular safety of weight loss drug

Fish oil supplements do not reduce risk of cardiovascular events in patients with diabetes

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News